CLEVELAND, Dec. 16 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced the release of its version 9.0 eClinical Software. This release advances the Company's singular vision for product and service delivery and introduces two new mechanisms for facilitating DATATRAK ONE's Knowledge(TM) offering: the DATATRAK Learning Center(TM) and the DATATRAK Learning Manager(TM).
The release also includes functionality enhancements for end users as well as clinical trial designers. System end users have greater flexibility in dynamically managing their data through new tools as well as advanced filtering in existing tools. The tool kit for clinical trial designers has been enhanced with new error checking, additional commands and more efficient workflows. Please see http://www.datatrak.net for more information.
"As evidenced by the evolution of our DATATRAK ONE(TM) vision, DATATRAK is committed to providing technology leadership to our clients," stated DATATRAK's CEO, Laurence Birch. "Our substantial investment in Research and Development allows for the continual expansion of our platform and signifies our commitment to our customers."
Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the costs associated with maintaining and/or developing two product suites; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.
CONTACT: Raymond J. Merk, Chief Financial Officer and Chief Operating
Officer of DATATRAK International, Inc., +1-440-443-0082 x181
Web site: http://www.datatrak.net/
